Urotropine; 1,3,5,7- tetraazaadamantane, Formin, Aminoform
|Jmol 3D model||Interactive image|
|Molar mass||140.186 g/mol|
|Appearance||White crystalline solid|
|Density||1.33 g/cm3 (at 20 °C)|
|Melting point||280 °C (536 °F; 553 K) (sublimes)|
|85.3 g/100 mL|
|Main hazards||Highly flammable, harmful|
|Flash point||250 °C (482 °F; 523 K)|
|410 °C (770 °F; 683 K)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Hexamethylenetetramine or methenamine is a heterocyclic organic compound with the formula (CH2)6N4. This white crystalline compound is highly soluble in water and polar organic solvents. It has a cage-like structure similar to adamantane. It is useful in the synthesis of other chemical compounds, e.g., plastics, pharmaceuticals, rubber additives. It sublimes in vacuum at 280 °C.
Synthesis, structure, reactivity
The molecule has a symmetric tetrahedral cage-like structure, similar to adamantane, whose four "corners" are nitrogen atoms and "edges" are methylene bridges. Although the molecular shape defines a cage, no void space is available at the interior for binding other atoms or molecules, unlike crown ethers or larger cryptand structures.
The molecule behaves like an amine base, undergoing protonation and N-alkylation.
The dominant use of hexamethylenetetramine is in the production of powdery or liquid preparations of phenolic resins and phenolic resin moulding compounds, where it is added as a hardening component. These products are used as binders, e.g. in brake and clutch linings, abrasive products, non-woven textiles, formed parts produced by moulding processes, and fireproof materials.
As the mandelic acid salt (generic methenamine mandelate, USP) it is used for the treatment of urinary tract infection. It decomposes at an acidic pH to form formaldehyde and ammonia, and the formaldehyde is bactericidal; the mandelic acid adds to this effect. Urinary acidity is typically ensured by co-administering vitamin C (ascorbic acid) or ammonium chloride. Its use had temporarily been reduced in the late 1990s, due to adverse effects, particularly chemically-induced hemorrhagic cystitis in overdose, but its use has now been re-approved because of the prevalence of antibiotic resistance to more commonly used drugs. This drug is particularly suitable for long-term prophylactic treatment of urinary tract infection, because bacteria do not develop resistance to formaldehyde. It should not be used in the presence of renal insufficiency. Methenamine in the form of cream and spray is successfully used for treatment of excessive sweating and related to it odour.
- Grocott's methenamine silver stain, used widely as a screen for fungal organisms.
- Jones' stain, a methenamine silver-Periodic acid-Schiff that stains for basement membrane, availing to view the "spiked" Glomerular basement membrane associated with membranous glomerulonephritis.
Together with 1,3,5-trioxane, hexamethylenetetramine is a component of hexamine fuel tablets used by campers, hobbyists, the military and relief organizations for heating camping food or military rations. It burns smokelessly, has a high energy density of 30.0 megajoules per kilogram (MJ/kg), does not liquify while burning, and leaves no ashes.
Hexamethylene tetramine or hexamine is also used as a food additive as a preservative (INS number 239). It is approved for usage for this purpose in the EU, where it is listed under E number E239, however it is not approved in the USA, Russia, Australia, or New Zealand.
Reagent in organic chemistry
Hexamethylenetetramine is a versatile reagent in organic synthesis. It is used in the Duff reaction (formylation of arenes), the Sommelet reaction (converting benzyl halides to aldehydes), and in the Delepine reaction (synthesis of amines from alkyl halides).
Hexamethylenetetramine was first introduced into the medical setting in 1899 as a urinary antiseptic. However, it was only used in cases of acidic urine, whereas boric acid was used to treat urinary tract infections with alkaline urine. Scientist De Eds found that there was a direct correlation between the acidity of hexamethylenetetramine's environment and the rate of its decomposition. Therefore, its effectiveness as a drug depended greatly on the acidity of the urine rather than the amount of the drug administered. In an alkaline environment, hexamethylenetetramine was found to be almost completely inactive.
Hexamethlyenetetramine was also used as a method of treatment for soldiers exposed to phosgene in World War I. Subsequent studies have shown that large doses of hexamethylenetetramine provide some protection if taken before phosgene exposure but none if taken afterwards.
Since 1990 the number of European producers has been declining. The French SNPE factory closed in 1990; in 1993, the production of hexamethylenetetramine in Leuna, Germany ceased; in 1996, the Italian facility of Agrolinz closed down; in 2001, the UK producer Borden closed; in 2006, production at Chemko, Slovak Republic, was closed. Remaining producers include INEOS in Germany, Caldic in the Netherlands, and Hexion in Italy. In the US, Eli Lilly and Company stopped producing methenamine tablets in 2002. In Australia, Hexamine Tablets for fuel are made by Thales Australia Ltd. In México, Hexamine is produced by Abiya.
- Cooney, A. P.; Crampton, M. R.; Golding, P. (1986). "The acid-base behaviour of hexamine and its N-acetyl derivatives". J. Chem. Soc., Perkin Trans. 2 (6): 835. doi:10.1039/P29860000835.
- Butlerow, A. (1859). "Ueber einige Derivate des Jodmethylens" [On some derivatives of methylene iodide]. Ann. Chem. Pharm. (in German). 111 (2): 242–252. doi:10.1002/jlac.18591110219.
- Butlerow, A. (1860). "Ueber ein neues Methylenderivat" [On a new methylene derivative]. Ann. Chem. Pharm. (in German). 115 (3): 322–327. doi:10.1002/jlac.18601150325.
- Eller, K.; Henkes, E.; Rossbacher, R.; Höke, H. (2000). "Amines, Aliphatic". Ullmann's Encyclopedia of Industrial Chemistry. Wiley-VCH Verlag GmbH. doi:10.1002/14356007.a02_001. ISBN 9783527306732.
- Markle, R. C. (2000). "Molecular building blocks and development strategies for molecular nanotechnology". Nanotechnology. 11: 89. doi:10.1088/0957-4484/11/2/309.
- Garcia, J. C.; Justo, J. F.; Machado, W. V. M.; Assali, L. V. C. (2009). "Functionalized adamantane: building blocks for nanostructure self-assembly". Phys. Rev. B. 80: 125421. doi:10.1103/PhysRevB.80.125421.
- "Methenamine mandelate, USP". Edenbridge Pharmaceuticals.
- Ross, R. R.; Conway, G. F. (1970). "Hemorrhagic cystitis following accidental overdose of methenamine mandelate". Am. J. Dis. Child. 119 (1): 86–87. doi:10.1001/archpedi.1970.02100050088021. PMID 5410299.
- Alan H. Schoen (2004), Re: Equialence of methenamine Tablets Standard for Flammability of Carpets and Rugs. U.S. Consumer product Safety Commission, Washington, DC, July 29, 2004. Many other countries who still produce this include Russia, Saudi Arabia, China and Australia.
- UK Food Standards Agency: "Current EU approved additives and their E Numbers". Retrieved 2011-10-27.
- Australia New Zealand Food Standards Code"Standard 1.2.4 - Labelling of ingredients". Retrieved 2011-10-27.
- Blažzević, N.; Kolbah, D.; Belin, B.; Šunjić, V.; Kajfež, F. (1979). "Hexamethylenetetramine, A Versatile Reagent in Organic Synthesis". Synthesis. 1979 (3): 161–176. doi:10.1055/s-1979-28602.
- Allen, C. F. H.; Leubne, G. W. (1951). "Syringic Aldehyde". Org. Synth. 31: 92. doi:10.15227/orgsyn.031.0092.
- Wiberg, K. B. (1963). "2-Thiophenaldehyde". Org. Synth. doi:10.15227/orgsyn.000.0000.; Coll. Vol., 3, p. 811
- Bottini, A. T.; Dev, V.; Klinck, J. (1963). "2-Bromoallylamine". Org. Synth. 43: 6. doi:10.15227/orgsyn.043.0006.
- Heathcote, Reginald St. A. (1935). "HEXAMINE AS AN URINARY ANTISEPTIC: I. ITS RATE OF HYDROLYSIS AT DIFFERENT HYDROGEN ION CONCENTRATIONS. II. ITS ANTISEPTIC POWER AGAINST VARIOUS BACTERIA IN URINE". British Journal of Urology. 7 (1): 9–32. doi:10.1111/j.1464-410X.1935.tb11265.x. ISSN 0007-1331.
- Elliot (1913). "On Urinary Antiseptics". British Medical Journal. 98: 685–686.
- Diller, Werner F. (1980). "The methenamine misunderstanding in the therapy of phosgene poisoning (review article)". Archives of Toxicology. 46 (3-4): 199–206. doi:10.1007/BF00310435. ISSN 0340-5761.